Influenza can result in serious complications, hospitalization, and death. Annual vaccination is the primary means of preventing influenza and is recommended by the Centers for Disease Control and Prevention (CDC).7

Recommendation

  • The Advisory Committee on Immunization Practices recommends routine influenza vaccination for all persons aged ≥6 months who do not have contraindications2
  • Healthcare providers should offer vaccination by the end of October, if possible2
  • Children aged 6 months through 8 years, who require 2 doses, should receive their first dose as soon as possible after the vaccine becomes available, and the second dose ≥4 weeks later2

People at high risk

  • Although anyone can be susceptible to contracting influenza, certain groups are at increased risk of flu complications7

Children aged 6 through 35 months

Children Flu Facts

The CDC estimates that over
15,000
children under the age of 5
were hospitalized because of flu complications during the 2015-2016 Influenza season8

Children FF Pie Chart

Roughly 30% of children aged 6 months to 4 years were not vaccinated for the flu during the 2014-2015 season (based on the most recent data)9,*

Adults aged 65 years and older

In recent years, the CDC estimates people aged 65 years and older have accounted for10:

  • 71%-85% of seasonal flu-related deaths
  • 54%-70% of seasonal flu-related hospitalizations

Other high-risk groups

  • Pregnant women11
  • People with certain medical conditions, such as asthma, heart disease, and diabetes11

For more information about influenza and high-risk populations, please visit the CDC.

* The CDC analyzed data sourced from the National Immunization Survey-Flu (NIS-Flu) with an unweighted sample size of 37,626 subjects aged 6 months to 4 years.9

FAQs for FLULAVAL QUADRIVALENT and FLUARIX QUADRIVALENT (Influenza Vaccine)

FLULAVAL and FLUARIX are registered trademarks of the GSK group of companies.

Indication

FLULAVAL QUADRIVALENT is a vaccine indicated for active immunization for the prevention of disease caused by influenza A subtype viruses and type B viruses contained in the vaccine. FLULAVAL QUADRIVALENT is approved for use in persons aged 6 months and older.

Important Safety Information for FLULAVAL QUADRIVALENT

  • Do not administer FLULAVAL QUADRIVALENT to anyone with a history of severe allergic reactions (eg, anaphylaxis) to any component of the vaccine, including egg protein, or following a previous dose of any influenza vaccine
  • If Guillain-Barré syndrome has occurred within 6 weeks of receipt of a prior influenza vaccine, the decision to give FLULAVAL QUADRIVALENT should be based on careful consideration of the potential benefits and risks
  • Syncope (fainting) can occur in association with administration of injectable vaccines, including FLULAVAL QUADRIVALENT. Procedures should be in place to avoid falling injury and to restore cerebral perfusion following syncope
  • If FLULAVAL QUADRIVALENT is administered to immunosuppressed persons, including individuals receiving immunosuppressive therapy, the immune response may be lower than in immunocompetent persons
  • In clinical trials with FLULAVAL QUADRIVALENT in adults, the most common solicited local adverse reaction was pain and the most common solicited systemic adverse reactions were muscle aches, headache, fatigue, and arthralgia. In children 6 through 35 months of age, the most common solicited local adverse reaction was pain and the most common solicited systemic adverse reactions were irritability, drowsiness, and loss of appetite. In children 3 through 17 years of age, the most common solicited local adverse reaction was pain. In children 3 through 4 years of age, the most common solicited systemic adverse reactions were irritability, drowsiness, and loss of appetite. In children 5 through 17 years of age, the most common solicited systemic adverse reactions were muscle aches, fatigue, headache, arthralgia, and gastrointestinal symptoms. (See Adverse Reactions section of the Prescribing Information for FLULAVAL QUADRIVALENT for other potential adverse reactions and events)
  • Vaccination with FLULAVAL QUADRIVALENT may not result in protection in all vaccine recipients

Please see full Prescribing Information for FLULAVAL QUADRIVALENT.

View all references.

 

819254R0 September 2017